Approvals/TGA/NUCALA mepolizumab 100 mg solution for injection in pre-filled syringe

Approved

STANDARD

NUCALA mepolizumab 100 mg solution for injection in pre-filled syringe

GlaxoSmithKline Australia Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: 2872f71240094076
Product Name: NUCALA mepolizumab 100 mg solution for injection in pre-filled syringe
Artg Id: 312652
Artg Name: NUCALA mepolizumab 100 mg solution for injection in pre-filled syringe
Sponsor: GlaxoSmithKline Australia Pty Ltd
Company Detail Path: /organization/glaxosmithkline-australia-pty-ltd
Artg Date: 2019-12-02
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2019-CMI-02418-1
Product Information: http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent=&id=CP-2016-PI-01215-1

Approved

Agency

TGA

Country

🇦🇺

Approval Date

Dec 9, 2025

Approval ID

2872f71240094076

Type

Standard